亚洲字幕成人中文在线观看,日韩久久网,欧美日韩一,操日本女人逼视频,国产欧美123,久久久久av,欧美久久久久久久久中文字幕

產(chǎn)品分類導航
Retatrutide for Weight Loss: Triple-Action Therapy for Obesity Management
Retatrutide for Weight Loss: Triple-Action Therapy for Obesity Management
Retatrutide for Weight Loss: Triple-Action Therapy for Obesity Management
Retatrutide for Weight Loss: Triple-Action Therapy for Obesity Management
Retatrutide for Weight Loss: Triple-Action Therapy for Obesity Management
Retatrutide for Weight Loss: Triple-Action Therapy for Obesity Management
Retatrutide for Weight Loss: Triple-Action Therapy for Obesity Management

Retatrutide for Weight Loss: Triple-Action Therapy for Obesity Management

更新時間:2025-06-20

價格:  元/個
CAS號: 2381089-83-2
藥典: 中國藥典,企業(yè)標準
級別: injection
立即詢盤
收藏
產(chǎn)品詳情
產(chǎn)品關(guān)鍵詞: Triple-Action Agonist,Type 2 Diabetes and Weight Management,GIP/GLP-1/GCG Receptor Activation,Once-Weekly Dosing,Innovative Obesity Therapy
是否為生產(chǎn)商:
產(chǎn)品包裝規(guī)格: 10mg/Ampoule 15mg/Ampoule 20mg/Ampoule 10Ampoules/Box
付款方式: TT L/C
交貨周期: in 45 days
主要銷售市場: 中國,北美洲,中/南美洲,西歐,東歐,大洋洲,亞洲,中東,非洲
產(chǎn)品描述:


Mechanism of Action

Retatrutide is a triple-agonist peptide that simultaneously activates three key metabolic receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This unique mechanism provides comprehensive metabolic benefits:

  1. GLP-1 Receptor Activation:Enhances glucose-dependent insulin secretion, improving postprandial glucose control.Slows gastric emptying, promoting satiety and reducing food intake.Suppresses glucagon secretion, further aiding in glucose regulation.
  2. GIP Receptor Activation:Stimulates insulin secretion in a glucose-dependent manner, enhancing insulin sensitivity.Contributes to fat metabolism and preservation of β-cell function.
  3. Glucagon Receptor Activation:Increases energy expenditure through hepatic glucose output and lipid mobilization.Promotes fatty acid oxidation and thermogenesis, supporting weight reduction.
  4. The combination of these actions results in a synergistic effect that enhances weight loss, improves glycemic control, and optimizes overall metabolic health.

Applications

  1. Type 2 Diabetes Management: Retatrutide helps regulate blood glucose levels and improve glycemic control.
  2. Weight Management: It has demonstrated significant weight loss benefits, making it suitable for obesity management.
  3. Non-Alcoholic Fatty Liver Disease (NAFLD): Retatrutide has shown potential in reducing liver fat content.
  4. Metabolic Syndrome: It addresses multiple aspects of metabolic dysfunction, including lipid metabolism and energy expenditure.

Dosage Instructions

  1. Initial Dose: The starting dose is typically 2.5 mg once weekly.
  2. Titration: The dose can be increased to 5 mg, 10 mg, or higher, depending on individual response and tolerability.
  3. Injection Instructions: Administered subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites to avoid lipodystrophy.
  4. Missed Dose: If a dose is missed, administer as soon as possible within 3 days. If more than 3 days have passed, skip the missed dose and resume the regular schedule.

Storage

  1. Unopened Pens: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.
  2. Opened Pens: Once opened, pens can be stored at room temperature (not exceeding 30°C/86°F) for up to 8 weeks.
  3. Protection from Light and Heat: Keep the medication away from direct sunlight and high temperatures.
上海浦津林州制藥有限公司
注冊資本
聯(lián)系人
聯(lián)系電話
查看聯(lián)系方式
快速詢盤
詢盤主題
請輸入詢盤主題
詢盤信息
請輸入詢盤信息
滑動驗證
請完成滑塊驗證
快速發(fā)送詢盤
CPHI制藥在線為您找到Retatrutide for Weight Loss: Triple-Action Therapy for Obesity Management 價格、Retatrutide for Weight Loss: Triple-Action Therapy for Obesity Management 詳細參數(shù)、Retatrutide for Weight Loss: Triple-Action Therapy for Obesity Management 相關(guān)產(chǎn)品、Retatrutide for Weight Loss: Triple-Action Therapy for Obesity Management 供應(yīng)商等信息,想了解當前Retatrutide for Weight Loss: Triple-Action Therapy for Obesity Management 最新報價,請聯(lián)系上海浦津林州制藥有限公司。
2006-2025 上海博華國際展覽有限公司版權(quán)所有(保留一切權(quán)利) 滬ICP備05034851號-57
建湖县| 涪陵区| 上林县| 栾城县| 凤山市| 双江| 丁青县| 阿拉善左旗| 宁波市| 霞浦县| 九寨沟县| 营口市| 南乐县| 濮阳市| 宜宾市| 巩留县| 临漳县| 抚顺市| 铜山县| 永德县| 台东县| 陆丰市| 沅江市| 息烽县| 勃利县| 射阳县| 武山县| 平顺县| 宁武县| 灵石县| 手游| 凤阳县| 乌拉特后旗| 六枝特区| 红原县| 长葛市| 中江县| 定南县| 平谷区| 徐州市| 沾化县|